18 completed, 1 terminated. 14 Phase 1, 4 Phase 2, 1 Phase 3.
By phase and status
Follow Tibotec BVBA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin placebo., TMC649128., placebo - Hepatitis C Virus Phase 1 Terminated 14 2011-06-01 2012-10-26 TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions Moxifloxacin, TMC207, TMC207 placebo - Healthy Volunteer Phase 1 Completed 88 2011-02-01 2012-11-06 Drug-Drug Interaction Study Between Telaprevir and Buprenorphine telaprevir, buprenorphine/naloxone - Hepatitis C, Opioid-Related Disorders Phase 1 Completed 16 2011-01-01 2011-06-08 VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir Treatment sequence AB, Treatment sequence BA - Hepatitis C Phase 1 Completed 21 2010-12-01 2012-10-16 A Study of TMC207 in Patients With Moderately Impaired Hepatic Function TMC207 - Moderate Hepatic Impairment Phase 1 Completed 16 2010-01-01 2012-12-20 VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers Telaprevir; Moxifloxacin; Placebo - Hepatitis C Phase 1 Completed 44 2009-10-01 2010-12-17 VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram Telaprevir; Escitalopram - Hepatitis C Phase 1 Completed 16 2009-09-01 2010-12-17 A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants Treatment A, Treatment B, Treatment C - Healthy Phase 1 Completed 28 2009-08-01 2013-03-19 A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State Telaprevir, Methadone - Healthy Participants Phase 1 Completed 18 2009-07-01 2012-12-03 TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP) TMC207; nevirapine - HIV Infections Phase 1 Completed 16 2009-06-01 2014-04-02 VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir. telaprevir - Hepatitis C, Kidney Diseases Phase 1 Completed 24 2009-06-01 2010-12-17 VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer Efavirenz; Tenofovir disoproxil fumarate; Telaprevir - Hepatitis C, HCV Phase 1 Completed 20 2009-02-01 2010-12-17 TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer TMC207 - Tuberculosis, HIV Phase 1 Completed 16 2009-02-01 2012-08-15 A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment Telaprevir, Peg-IFN-alfa-2a, Ribavirin - Hepatitis C, Chronic Phase 3 Completed 663 2008-10-01 2014-01-22 VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state. Telaprevir; Darunavir; Ritonavir; Fosamprenavir - Hepatitis C, Telaprevir Phase 1 Completed 40 2008-06-01 2010-12-17 An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection Telaprevir, Pegylated-interferon-alfa-2a, Placebo - Hepatitis C Phase 2 Completed 24 2008-01-01 2013-09-09 A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection Telaprevir, Peg-IFN-alfa-2a + Ribavirin (Standard Treatment), Placebo - Hepatitis C, Chronic Phase 2 Completed 52 2007-12-01 2013-06-17 An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants Telaprevir, Peg-IFN-alfa-2a, Peg-IFN-alfa-2b - Chronic Hepatitis C Phase 2 Completed 166 2007-10-01 2014-06-25 TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis TMC207 - Tuberculosis Phase 2 Completed 75 2005-05-01 2012-08-15
Conditions studied Hepatitis C (9) · Tuberculosis (4) · HIV Infections (3) · Hepatitis C, Chronic (3) · Hepatitis (2) · Acquired Immunodeficiency Syndrome (1) · Kidney Diseases (1) · Opioid-Related Disorders (1)
Interventions telaprevir (11) · bedaquiline (5) · Ribavirin (4) · peginterferon alfa-2a (4) · Moxifloxacin (2) · Buprenorphine, Naloxone Drug Combination (1) · Capsules (1) · Darunavir (1) · Escitalopram (1) · Methadone (1) · Nevirapine (1) · Ritonavir (1) · Tenofovir (1) · efavirenz (1) · fosamprenavir (1)
Countries France (3) · Netherlands (3) · Austria (2) · Belgium (2) · Germany (2) · Poland (2) · Spain (2) · Sweden (2) · United Kingdom (2) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · Israel (1) · Puerto Rico (1)
Top investigators Scott McCallister, M.D. (1)
Results publications PMID 25114140 , PMID 18505852 , PMID 21696308 , PMID 22387529 , PMID 23321318 , PMID 23478952 , PMID 24382638 , PMID 24486089 , PMID 24886541
NIH funding 2009 (1)